EMA Recommends Extension of Therapeutic Indications for Acalabrutinib By Ogkologos - June 18, 2025 833 0 Facebook Twitter Google+ Pinterest WhatsApp A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Investment Needed to Bring Down Pancreatic Cancer Death Rates in Europe.... February 22, 2021 A Phase III Study of Spartalizumab in Combination with Dabrafenib and... January 20, 2022 Adding Durvalumab to First-Line Platinum-Based Chemotherapy Followed by Maintenance Durvalumab With... November 14, 2023 FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive,... November 20, 2024 Load more HOT NEWS A vision for the next decade of UK life sciences Breast Cancer May Spread by Recruiting Nearby Sensory Nerves Man Becomes Nervous About How Cop Acts During Ticket, Then He... Fisioterapeutas en oncología
